Results 51 to 60 of about 2,525 (153)

Chronic Pulmonary Aspergillosis Secondary Infection: A Case Report of Achromobacter spp. Lung Infection

Clinical Case Reports, Volume 13, Issue 10, October 2025.
ABSTRACT Both pulmonary tuberculosis (PTB) and coronavirus disease‐2019 (COVID‐19) are risk factors for chronic pulmonary aspergillosis (CPA) and other pulmonary infectious diseases because of residual lung damage. We report a case of Achromobacter spp. infection following CPA in an immunocompetent woman with a history of PTB and COVID‐19.
Marius Paulin Ngouanom Kuate, Felix Bongomin, David W. Denning   +2 more
wiley   +1 more source

Investigation on Klebsiella pneumoniae in the field of extracellular vesicles

Interdisciplinary Medicine, Volume 3, Issue 4, July 2025.
The role of extracellular vesicles in the pathogenicity and antibiotic resistance, as well as treatment and prevention of Klebsiella pneumoniae. Abstract Klebsiella pneumoniae (KP), recognized for its pronounced antibiotic resistance, is a prevalent agent of nosocomial infections such as hospital‐acquired pneumonia.
Junwei Wu, Yuheng Liu, Jin Su, Yi Yang, Haiyi Deng, Yilin Yang, Mengxi Yanglan, Xinyi Wu, Shiqi Luo, Yao Liao, Lifu Wang   +10 more
wiley   +1 more source

Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City [PDF]

Antimicrobial Agents and Chemotherapy, 2015
ABSTRACT Imipenem with relebactam was active against Escherichia coli , Klebsiella pneumoniae , and Enterobacter spp., including K. pneumoniae carbapenemase (KPC)-producing isolates.
Amabel, Lapuebla, Marie, Abdallah, Olawole, Olafisoye, Christopher, Cortes, Carl, Urban, David, Landman, John, Quale   +6 more
openaire   +2 more sources

A Review of In Silico and In Vitro Approaches in the Fight Against Carbapenem‐Resistant Enterobacterales

Journal of Clinical Laboratory Analysis, Volume 39, Issue 9, May 2025.
This review highlights computational approaches for discovering antimicrobials against carbapenem‐resistant Enterobacterales. It outlines methods like pharmacophore modeling, molecular docking, and absorption, distribution, metabolism, and excretion–toxicity (ADMET) analysis, integrated with in vitro assays, to identify and validate potential drugs ...
Muhammad Absar, Abdul Rahman Zaidah, Amer Mahmood, Sajjad Ahmad, Hasan Ejaz, Naveed Ahmed, Nik Haszroel Hysham Nik Hashim, Chan Yean Yean   +7 more
wiley   +1 more source

Association of Vancomycin Plus Piperacillin‐Tazobactam With Acute Kidney Injury: Differentiating Pseudo‐Injury From True Nephrotoxicity

Clinical and Translational Science, Volume 18, Issue 5, May 2025.
ABSTRACT The combination of vancomycin and piperacillin‐tazobactam (VPT) is widely used for severe infections, but its potential synergistic nephrotoxicity remains debated. This study used the FDA Adverse Event Reporting System (FAERS) database via AERSMine to assess the risk of AKI with VPT and vancomycin plus carbapenems (VC), compared to other ...
Congqin Chen, Rijing Zhou, Jie Fang, Jie Xiao   +3 more
wiley   +1 more source

A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date.

Infection and drug resistance, 2020
Imipenem-relebactam (I-R) is a novel beta-lactam/beta-lactamase inhibitor combination given with cilastatin. It is indicated for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and hospital-acquired or ventilator-associated bacterial pneumonia.
Campanella,Toni A, Gallagher,Jason C
openaire   +5 more sources

Occurrence and spread of carbapenemase‐producing Enterobacterales (CPE) in the food chain in the EU/EFTA. Part 1: 2025 update

EFSA Journal, Volume 23, Issue 4, April 2025.
Abstract Carbapenemase‐producing Enterobacterales (CPE) have been reported in the food chain in 14 out of 30 EU/EFTA countries. Commonly reported genes are blaVIM‐1, blaOXA‐48 and blaOXA‐181, followed by blaNDM‐5 and blaIMI‐1. Escherichia coli, target of most of the studies, Enterobacter cloacae complex, Klebsiella pneumoniae complex and Salmonella ...
EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards), Ana Allende, Avelino Álvarez‐Ordóñez, Valeria Bortolaia, Sara Bover‐Cid, Alessandra De Cesare, Wietske Dohmen, Laurent Guillier, Lieve Herman, Liesbeth Jacxsens, Lapo Mughini‐Gras, Maarten Nauta, Jakob Ottoson, Fernando Pérez‐Rodríguez, Panagiotis Skandamis, Elisabetta Suffredini, Hector Argüello, Johan Bengtsson‐Palme, Alessandra Carattoli, Anke Kohlenberg, Dominique L. Monnet, Laurent Poirel, Beatriz Guerra, Raquel García‐Fierro, Ernesto Liébana, Sonagnon Martin Goudjihounde, Núria Ferrer‐Bustins, Hanne Rabbås, Luisa Peixe   +28 more
wiley   +1 more source

Wash‐free fluorescent tools based on organic molecules: Design principles and biomedical applications

Exploration, Volume 5, Issue 1, February 2025.
In this review, the design principles for wash‐free molecular fluorescent tools are highlighted in four diverse details. Meanwhile, biomedical applications including wash‐free fluorescent imaging of organelles, cellular microenvironment, biomacromolecules, and small species, as well as therapy and potential drug delivery, are also emphasized.
Jingyun Tan, Chunfei Wang, Zhangjun Hu, Xuanjun Zhang   +3 more
wiley   +1 more source

Sulbactam–Durlobactam: A Novel Antibiotic Combination for the Treatment of Acinetobacter baumannii–Calcoaceticus Complex (ABC) Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial Pneumonia

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2025, Issue 1, 2025.
Purpose: To evaluate the pharmacology, pharmacokinetics, pharmacodynamics, antimicrobial activity, efficacy, safety, and the regulatory status of sulbactam–durlobactam. Summary: Sulbactam–durlobactam is a recently approved antimicrobial combination of two β‐lactamase inhibitors for the treatment of hospital‐acquired bacterial pneumonia (HABP) and ...
Wissam K. Kabbara, Elina Sadek, Hanine Mansour, Vijay Gondil   +3 more
wiley   +1 more source

Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains

Infection and Drug Resistance, 2022
Ryota Ito, Masato Kawamura, Takumi Sato, Shigeru Fujimura Tohoku Medical and Pharmaceutical University, Division of Clinical Infectious Diseases & Chemotherapy, Sendai, Miyagi, JapanCorrespondence: Ryota Ito, Tohoku Medical and Pharmaceutical University,
Ito R, Kawamura M, Sato T, Fujimura S
doaj